Identifying Molecular Targets for New Bipolar Disorder Drugs

Bipolar Disorder (BD) is the 4th leading cause of disability amongst 10-24-year-olds. This illness is characterized by recurrent episodes of mania and depression, with 7% of BD patients die by suicide, representing a significant public health concern. Since BD patients spend half of their life experiencing mood symptoms despite treatments, identifying novel therapies that are effective and tolerated, along with the discovery of their yet unidentified molecular targets, are urgently needed. By leveraging the latest advances in proteomics, stem cell research, and artificial-intelligence (AI), we propose to develop long-term treatments of BD. Specifically, we aim to: (1) uncover common molecular targets of four select atypical FDA approved or currently reviewed BD antipsychotics; and (2) implement an AI-augmented platform to discover novel drugs for BD. These will be accomplished by partnering with 99andBeyond, who will benefit by commercializing the IP to deliver a novel and effective BD drugs to patients.

Faculty Supervisor:

Mohan Babu

Student:

Partner:

99andBeyond Inc.

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

University of Regina

Program:

Accelerate

Related projects

Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.

View all
Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Find Projects

Mitacs Partners

The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.

Government
Academic
Industry
Innovation
International

International

Load More

International

Load More

Join a thriving innovation ecosystem.

Subscribe to our newsletter now!

Subscribe

Mitacs — Return on Innovation

Mitacs is funded by the Government of Canada, the Government of Alberta, the Government of British Columbia, Research Manitoba, the Government of New Brunswick, the Government of Newfoundland and Labrador, the Government of Nova Scotia, the Government of Ontario, Innovation PEI, the Government of Quebec, the Government of Saskatchewan, and the Government of Yukon.